Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial

BACKGROUND: We recently conducted Cetuximab-AVElumab-Lung (CAVE-Lung), a proof-of-concept, translational and clinical trial, to evaluate the combination of two IgG1 monoclonal antibodies (mAb): avelumab, an anti-PD-L1 drug, and cetuximab, an anti-epidermal growth factor receptor (EGFR) drug, as seco...

Descripción completa

Detalles Bibliográficos
Autores principales: Della Corte, Carminia Maria, Fasano, Morena, Ciaramella, Vincenza, Cimmino, Flora, Cardnell, Robert, Gay, Carl M., Ramkumar, Kavya, Diao, Lixia, Di Liello, Raimondo, Viscardi, Giuseppe, Famiglietti, Vincenzo, Ciardiello, Davide, Martini, Giulia, Napolitano, Stefania, Tuccillo, Concetta, Troiani, Teresa, Martinelli, Erika, Wang, Jing, Byers, Lauren, Morgillo, Floriana, Ciardiello, Fortunato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962159/
https://www.ncbi.nlm.nih.gov/pubmed/35346313
http://dx.doi.org/10.1186/s13046-022-02332-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962159/
https://www.ncbi.nlm.nih.gov/pubmed/35346313
http://dx.doi.org/10.1186/s13046-022-02332-2

Ejemplares similares